Stock Guru Featured Client: Oncolin Therapeutics, Inc. (OCOL.OB)
Oncolin Therapeutics, Inc. (OCOL.OB) is a biopharmaceutical company working toward developing drugs that will interfere with cancer tumor development. Oncolin is also focused on discovering, developing, and commercializing anti-cancer therapies, and has a lead brain cancer drug in preclinical development. The company extends their research with many oncology research programs funded by federal grants. Oncolin’s brain cancer drug is licensed from the MD Anderson Cancer Center. The company is determined to develop this drug, and anticipates filing an Investigational New Drug application with the FDA. In preclinical testing, Oncolin’s lead drug revealed its ability to extend the life of animals…
